Kazia Therapeutics Licenses Cantrixil To Oasmia Pharmaceutical For Ovarian Cancer
Kazia Therapeutics Ltd (NASDAQ: KZIA) has entered an exclusive worldwide licensing agreement with Oasmia Pharmaceutical AB (OTCMKTS: OASMY) for Cantrixil under development the treatment of ovarian can...